Priority review to Roche’s bispecific antibody glofitamab for large B-cell lymphoma

 

• If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin lymphoma

• Results from the pivotal phase I/II NP30179 study showed glofitamab induced durable response rates in people with heavily pre-treated large B-cell lymphoma, with 40% achieving a complete response

• Glofitamab is part of Roche’s industry-leading portfolio of T-cell engaging bispecific antibodies, which also includes the newly FDA-approved first-in-class Lunsumio to treat follicular lymphoma

https://finance.yahoo.com/news/fda-grants-priority-review-roche-060000074.html